Johnatty Sharon E, Tudini Emma, Parsons Michael T, Michailidou Kyriaki, Zanti Maria, Canson Daffodil, Davidson Aimee L, Berger Tamar, Rosti Rasim Ozgur, Kratz Christian P, Kalb Reinhard, McReynolds Lisa J, Giri Neelam, Richardson Marcy, Pesaran Tina, Surrallés Jordi, Pujol Roser, Vundinti Babu Rao, George Merin, Maxwell Kara N, Nathanson Kate, Domchek Susan, Fiesco-Roa Moisés Ó, Frias Sara, Garcia-de-Teresa Benilde, Jongmans Marjolijn, Lalani Seema, Maiburg Merel, Prescott Katrina, Robinson Rachel, Rajagopalan Sulekha, Blok Lot Snijders, Temple Suzanna E L, Tucker Kathy, Auerbach Arleen D, Cancio Maria I, Kennedy Jennifer A, MacMillan Margaret L, Tryon Rebecca, Wagner John E, Walsh Michael, Boddicker Nicholas J, Hu Chunling, Weitzel Jeffrey N, Dingemans Alexander J M, Hadler Johanna, Rotenberg Nitsan, Ramadane-Morchadi Lobna, de la Hoya Miguel, James Paul, Van Overeem Hansen Thomas, Vreeswijk Maaike P G, Walker Logan C, Sharan Shyam K, Easton Douglas F, Couch Fergus, Smogorzewska Agata, Nelson Adam, Ngeow Joanne, Tischkowitz Marc, Gomez-Garcia Encarnacion, Spurdle Amanda B
Population Health Program, QIMR Berghofer, Brisbane, Queensland, Australia.
These authors contributed equally.
medRxiv. 2025 May 26:2025.05.25.25327887. doi: 10.1101/2025.05.25.25327887.
Recessive Fanconi anemia (FA) phenotype is used in classification of , and variants with respect to dominant hereditary breast-ovarian cancer syndrome. We assessed its utility by examining the spectrum of phenotypes observed in individuals biallelic for , or pathogenic variants, and exploring the relationship between cancer presentation and allele severity score based on variant molecular features. A data collection instrument comprising 158 Human Phenotype Ontology (HPO) terms was used to document clinical features for individuals with FA from published and/or prospectively collected (total n=172, 43 previously unpublished) phenotypic data. Unique FA-related variants (15 , 123 , 22 ) were annotated for predicted molecular impact, location, observed splicing or functional impact, and potential in-frame splice rescue. Annotations were used to assign different permutations of allele severity scores, which were assessed for correlation with FA presentation features. The association of and allele severity score with magnitude of breast cancer risk in heterozygotes was evaluated using case-control analysis. Patient-detected features extended beyond the FA ORPHA:84 HPO list, including 84 terms related by hierarchy, and 94 novel terms. Genotype severity score was significantly associated with age at cancer diagnosis in FA individuals (p=1.8×10). A similar permutation approach revealed significant differences in magnitude of breast cancer risk according to and allele severity score in heterozygotes. Findings indicate potential to redefine the existing list of FA-related HPO terms, and to use an allele severity scoring approach to predict cancer risk in both FA patients and heterozygotes.
隐性范科尼贫血(FA)表型用于对与显性遗传性乳腺癌-卵巢癌综合征相关的 、 和 变体进行分类。我们通过检查双等位基因携带 、 或 致病变体的个体中观察到的表型谱,并基于变体分子特征探索癌症表现与等位基因严重程度评分之间的关系,来评估其效用。使用包含158个人类表型本体(HPO)术语的数据收集工具,记录已发表和/或前瞻性收集的FA个体(总共n = 172,43个先前未发表)的临床特征的表型数据。对独特的FA相关变体(15个 、123个 、22个 )进行注释,以预测分子影响、位置、观察到的剪接或功能影响以及潜在的框内剪接挽救。注释用于分配等位基因严重程度评分的不同排列,并评估其与FA表现特征的相关性。使用病例对照分析评估杂合子中 和 等位基因严重程度评分与乳腺癌风险大小的关联。患者检测到的特征超出了FA ORPHA:84 HPO列表,包括84个层次相关的术语和94个新术语。在 型FA个体中,基因型严重程度评分与癌症诊断年龄显著相关(p = 1.8×10)。类似的排列方法显示,根据杂合子中 和 等位基因严重程度评分,乳腺癌风险大小存在显著差异。研究结果表明,有可能重新定义现有的FA相关HPO术语列表,并使用等位基因严重程度评分方法来预测FA患者和杂合子的癌症风险。